ID: ALA3400486

Max Phase: Preclinical

Molecular Formula: C14H10ClN3OS

Molecular Weight: 303.77

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CN(c1ccc(Cl)cc1)c1nc(=O)c2ccncc2s1

Standard InChI:  InChI=1S/C14H10ClN3OS/c1-18(10-4-2-9(15)3-5-10)14-17-13(19)11-6-7-16-8-12(11)20-14/h2-8H,1H3

Standard InChI Key:  GFAHWKIXDXCZKX-UHFFFAOYSA-N

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 303.77Molecular Weight (Monoisotopic): 303.0233AlogP: 3.47#Rotatable Bonds: 2
Polar Surface Area: 46.09Molecular Species: NEUTRALHBA: 5HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 0.83CX LogP: 2.95CX LogD: 2.95
Aromatic Rings: 3Heavy Atoms: 20QED Weighted: 0.73Np Likeness Score: -1.58

References

1. Inami H, Shishikura J, Yasunaga T, Ohno K, Yamashita H, Kato K, Sakamoto S..  (2015)  Synthesis, structure-activity relationships, and anticonvulsant activities of 2-amino-4H-pyrido[3,2-e][1,3]thiazin-4-one derivatives as orally active AMPA receptor antagonists.,  23  (8): [PMID:25792143] [10.1016/j.bmc.2015.02.033]

Source